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The lack of a clear correlation between the levels of antibody to pertussis antigens and protection against
disease lends credence to the possibility that cell-mediated immunity provides primary protection against
disease. This phase I comparative trial had the aim of comparing the in vitro cellular immune response and
anti-pertussis toxin (anti-PT) immunoglobulin G (IgG) titers induced by a cellular pertussis vaccine with low
lipopolysaccharide (LPS) content (wPlow vaccine) with those induced by the conventional whole-cell pertussis
(wP) vaccine. A total of 234 infants were vaccinated at 2, 4, and 6 months with the conventional wP vaccine or
the wPlow vaccine. Proliferation of CD3
 T cells was evaluated by flow cytometry after 6 days of peripheral
blood mononuclear cell culture with stimulation with heat-killed Bordetella pertussis or phytohemagglutinin
(PHA). CD3, CD4, CD8, and T-cell receptor -positive () cells were identified in the gate of blast
lymphocytes. Gamma interferon, tumor necrosis factor alpha, interleukin-4 (IL-4), and IL-10 levels in super-
natants and serum anti-PT IgG levels were determined using enzyme-linked immunosorbent assay (ELISA).
The net percentage of CD3 blasts in cultures with B. pertussis in the group vaccinated with wP was higher than
that in the group vaccinated with the wPlow vaccine (medians of 6.2% for the wP vaccine and 3.9% for the wPlow
vaccine; P  0.029). The frequencies of proliferating CD4, CD8, and  cells, cytokine concentrations in
supernatants, and the geometric mean titers of anti-PT IgG were similar for the two vaccination groups. There
was a significant difference between the T-cell subpopulations for B. pertussis and PHA cultures, with a higher
percentage of  cells in the B. pertussis cultures (P< 0.001). The overall data did suggest that wP vaccination
resulted in modestly better specific CD3 cell proliferation, and  cell expansions were similar with the two
vaccines.
Efforts to immunize against whooping cough began almost
as soon as Bordet discovered the causative bacterium, Borde-
tella pertussis, in 1912 (8). A whole-cell pertussis (wP) vaccine
has been available since 1940. However, the road to eliminate
circulation of the pathogen has proven arduous. Throughout
the world, pertussis remains a major cause of morbidity and
mortality among infants (45). Some 20 million to 40 million
cases of disease occur worldwide each year, 90% of which are
found in developing countries (44).
Although no causal link between wP vaccination and per-
manent brain damage or death has been identified, concerns
about systemic reactions after immunization with a wP vac-
cine have been a major factor in its reduced acceptance in
developed countries (46). This has led to the development
of more-purified and less locally reactogenic acellular per-
tussis (aP) vaccines (21, 22, 43, 47). Similar immunogenici-
ties are obtained with both types of vaccine, as the most
efficacious vaccines of either category protect 80% of the
recipients from clinical disease. Moreover, the considerably
higher development costs of aP result in prices per dose that
are unlikely to be currently affordable for developing coun-
tries (46).
Lipopolysaccharide (LPS) possesses endotoxic activity and
also has powerful adjuvant activity. Both of these properties
are based upon the recognition of the LPS by the host Toll-like
receptor (TLR) complex TLR4/MD-2 and the subsequent ac-
tivation of NF-B (35). The relatively high reactogenicity of wP
vaccines has been associated with proinflammatory cytokines
(2, 28). Hence, a straightforward approach to reducing wP
reactogenicity would be the generation of a pertussis vaccine
with a reduced quantity of LPS. Furthermore, the lack of a
clear correlation between the levels of antibody (Ab) to per-
tussis antigens and protection against disease, the persistence
of protective immunity long after the disappearance of pertus-
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sis antigen-specific Ab, and the longer duration of T-cell re-
sponses to pertussis antigens lend credence to the possibility
that cell-mediated immunity provides primary protection
against disease (16, 34).
This phase I study was thus performed to obtain preliminary
immunogenicity data on a new cellular pertussis vaccine with
low LPS content (wPlow vaccine), in comparison to the con-
ventional wP vaccine used in Brazil, both of which are formu-
lated with diphtheria and tetanus toxoids and given in three
primary injections during infancy.
MATERIALS AND METHODS
Subjects. Infants scheduled to receive the first dose of pertussis vaccine were
recruited in Campinas Public Health Centers, Sa˜o Paulo, Brazil. A total of 247
infants were recruited to the study and randomized to receive three doses of
wPlow or wP vaccine at 2, 4, and 6 months of age. The preterm (gestational
age, 37 weeks) and low-birth-weight (weight, 2,500 g) newborns, infants
whose mothers were younger than 18 years old or had hepatitis B carrier status,
and infants with a family history of tuberculosis, syphilis, or human immunode-
ficiency virus infection were excluded. Exclusion criteria also included noncom-
pliance, receipt of immunoglobulin (Ig) therapy or blood products, and any
immunodeficiency, malignancy, or significant underlying disease or neurological
impairment.
Vaccines. Vaccines were manufactured by the Butantan Institute, Sa˜o Paulo,
Brazil. Bordetella pertussis cells were treated with an organic solvent and washed
in order to perform LPS extraction. The culture was then detoxified by the
addition of 0.2% formalin, and the bacterial biomass was obtained by tangential
flow filtration to formulate the wPlow vaccine.
Each 0.5-ml dose of either vaccine contained four protective units of pertussis
toxin and two protective units of diphtheria and tetanus toxoids. The antigens
were adsorbed onto 1.25 mg of aluminum hydroxide, and 0.2 mg of thimerosal
was used as a preservative. All infants received vaccine from the same batch. The
vaccines were visually indistinguishable and identically packaged and were ad-
ministered intramuscularly with the use of standard techniques.
Study design. This prospective, randomized, double-blind comparative trial
was conducted between August 2006 and July 2007 and followed the principles
outlined in the Declaration of Helsinki. Written informed consent was obtained
from all participants’ parents or legal guardians before study procedures were
initiated. The study protocol was approved by the Committee for Ethics in
Research of the State University of Campinas, Sa˜o Paulo, Brazil.
Antigens used in cell culture assays. A suspension of heat-killed B. pertussis
(lot IB-CIIn/P14/06; Butantan Institute), without thimerosal, was used at a con-
centration of 5  106 cells/ml. Phytohemagglutinin (PHA; Sigma) was used as a
positive control at 7.5 g/ml.
T-cell proliferation assay. Ten milliliters of heparinized peripheral blood was
collected and used for the evaluation of immune responses to pertussis vaccina-
tion at 7 months of age. The protocol for the proliferation assay was adapted
from the method of Gaines and Biberfeld (20). Peripheral blood mononuclear
cells (PBMC) were isolated by density gradient centrifugation over Ficoll-
Hypaque (Amersham Biosciences), washed, diluted to 1  106 cells/ml in RPMI
1640 medium (Sigma) supplemented with 10% human AB serum (Sigma), 1%
glutamine (Sigma), and 0.1% gentamicin, and stimulated for 6 days with heat-
killed B. pertussis, PHA, or medium alone at 37°C with 5% CO2 in round-bottom
96-well tissue culture plates (Nunc, Denmark). After being harvested with 20
mM EDTA, samples were incubated with human Ig and then stained with
anti-human CD3, CD4, CD8, and T-cell receptor (TCR) pan- fluorescent Abs
(Beckman Coulter) before acquisition (Epics XL-MCL flow cytometer; Beck-
man-Coulter) and analysis (Expo software; Beckman Coulter). Isotype controls
were used to discriminate positive populations (Beckman Coulter). Only CD3
T cells were used in analysis. Forward and side scatters were used to gate resting
and blast lymphocytes. Dead cells were excluded from all analyses. CD4, CD8,
and TCR -positive () cells were identified in the gating of blast lympho-
cytes. Proliferation was measured by percentages of CD3 blasts, in which basal
proliferation was subtracted from B. pertussis- and PHA-stimulated cultures.
Cytokine quantification in supernatants. For the cytokine quantification as-
say, PBMC were diluted to 2  106 cells/ml in supplemented RPMI medium and
incubated for 48 h in round-bottom 96-well tissue culture plates with B. pertussis,
PHA, or medium alone at 37°C. Supernatants were collected and stored at
	80°C. Gamma interferon (IFN-), tumor necrosis factor alpha (TNF-
), inter-
leukin-4 (IL-4), and IL-10 levels were determined in duplicate by a two-mono-
clonal-Ab sandwich enzyme-linked immunosorbent assay (ELISA) (R & D Sys-
tems) in flat-bottom MultiSorp ELISA plates (Nunc, Denmark), according to the
manufacturer’s protocols. Recombinant cytokine was used for the standard
curve. The limits of detection were 15.6 pg/ml for IFN- and TNF-
 and 31.2
pg/ml for IL-4 and IL-10.
Quantitative determination of anti-PT IgG. Quantitative determination of
anti-pertussis toxin (anti-PT) IgG was performed in a blind manner on serum
samples collected one month after the administration of the third dose of vaccine
and stored at 	80°C until tested. Using ELISA (32), anti-PT IgG levels were
calculated in IU/ml by comparison with a U.S. reference human antiserum (lot
3; Food and Drug Administration). To evaluate the titers, the values were
transformed into decimal logarithms, and then the means and the limits of the
95% confidence interval (CI) were determined. Thereafter, the antilogarithm
and the corresponding 95% CI were calculated.
Quantitative determination of anti-diphtheria toxin and anti-tetanus toxin
IgG. In vitro tests for measuring tetanus and diphtheria antitoxin levels in sera
from both vaccination groups were done by a standardized modified toxin-
binding inhibition assay (41) at the Quality Control Service of the Butantan
Institute, Sa˜o Paulo, Brazil.
Adverse event monitoring. Parents were asked to notify the study staff imme-
diately by phone of any unexpected or severe reactions. A standardized ques-
tionnaire using scripted questions and definitions was used to collect information
about any occurrence related to vaccination. After the first dose, parents’ com-
pliance to monitoring of adverse events was assessed by phone interview. At the
administrations of the second and third doses and blood sampling, compliance
was assessed by the study nurses during visits to the public health center.
Statistical considerations. Analyses were carried out with SPSS for Windows
(version 7.5.1). Mann-Whitney and Friedman nonparametric tests were used in
proliferation and cytokine analyses. Comparisons manifesting a two-tailed P
value of 0.05 were considered statistically significant. Prism software (version
4.0; GraphPad Software) was employed for the figures.
To evaluate the anti-PT titers, calculation of the geometric mean titers
(GMTs) of Abs was performed on log10-transformed data, and we report the
antilogarithms. For each group, GMTs and 95% CIs were calculated. For com-
parison of the logarithm of the titers, Student’s t test was applied for independent
samples. Comparisons manifesting a two-tailed P value of0.05 were considered
statistically significant (25).
The differences in the proportions of subjects with seroprotection against
diphtheria and tetanus and 90% CI were calculated as recommended for non-
inferiority studies (10, 36). Differences or ratios equal to or lower than 10% were
accepted as the limit for defining noninferiority of the wPlow vaccine. The null
hypothesis of noninferiority of the wPlow vaccine was accepted when the lower
limit of the CI was not lower than 	10%.
RESULTS
Study participants. Out of 247 infants initially selected, 234
participated in the entire study and were distributed as follows:
115 infants in the low-LPS-content vaccine group (57 males
and 58 females) and 119 infants in the whole-cell vaccine group
(65 males and 54 females). Table 1 shows the mean ages (with
standard deviations) of the infants at the administrations of the
three doses of vaccine and at blood sampling.
B. pertussis-specific T-cell proliferation. T-cell proliferation
was measured by flow cytometry (Fig. 1). CD3, CD4, and
CD8 immunophenotyping was carried out in the cultures of
205 infants, and  blast cells in 55 children (28 in the low-
LPS-content vaccine group) were analyzed.
Median background CD3 proliferation levels were 2.3% in
the wPlow vaccine group and 2.6% in the wP vaccine group.
The net percentage of CD3 blasts in cultures with B. pertussis
in the group vaccinated with the wP vaccine was higher than
that in the group vaccinated with the wPlow vaccine (medians
of 6.2% and 3.9% for those immunized with wP and wPlow
vaccines, respectively; P  0.029), but there was no difference
between these values for cultures stimulated with PHA (me-
dians of 82.5% and 81.4% for those immunized with wP and
wPlow vaccines, respectively; P  0.166) (Fig. 2).
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The frequencies of proliferating CD4, CD8, and  cells
in B. pertussis- and PHA-stimulated cultures were similar for
the vaccination groups (Table 2). On the other hand, there was
a significant difference between the T-cell subpopulations for
control and B. pertussis- and PHA-stimulated cultures (Fried-
man test, P  0.001), with higher percentages of  cells in
the B. pertussis-stimulated cultures.
B. pertussis-specific cytokine production. B. pertussis-specific
cytokines in cell cultures of infants were determined by ELISA
after 48 h of stimulation. For the groups of vaccinees, the
amounts of cytokine secretion in supernatants were compared.
IL-4 was undetectable in stimulated and unstimulated samples
(negative controls). Levels of IFN-, TNF-
, and IL-10 pro-
duction (Fig. 3) were not different between B. pertussis- and
PHA-stimulated cultures of infants vaccinated with the wPlow
or wP vaccine.
Anti-PT IgG titers. Anti-PT Ab GMTs following three doses
of wPlow or wP vaccine indicated robust responses to both
vaccines (Table 3), and no statistically significant differences
between the two groups were observed (Student’s t test, P 
0.464).
Diphtheria and tetanus seroprotection. Table 4 shows the
percentages (with 95% CIs) of subjects protected against diph-
FIG. 1. Flow cytometry of unstimulated (control) and B. pertussis- and PHA-stimulated PBMC of a 7-month-old infant vaccinated with a
cellular pertussis vaccine with low LPS content. After gating of CD3 cells (A), events were analyzed for size and complexity (forward-scatter and
side-scatter gates), from which resting and blast lymphocytes were separated (B). T-lymphocyte subsets (CD4, CD8, and ) were then verified
in blast lymphocytes.
FIG. 2. Distribution of CD3 blasts (percentages) determined by
flow cytometry of B. pertussis (Bp; f)- and PHA (Œ)-stimulated PBMC
from wPlow vaccine- or wP vaccine-immunized infants. Medians (indi-
cated by bars) of CD3 blasts in B. pertussis-stimulated cultures were
3.9% and 6.2% for wPlow and wP vaccines, respectively. Median per-
centages of CD3 blasts in PHA-stimulated cultures were 81.4% and
82.5%, respectively. n, number of individuals.
TABLE 1. Distributions of infants vaccinated with the wPlow or wP
vaccine by age at the administrations of the three doses of
vaccine and at blood sampling
Time Vaccine na Age (mo)b
1st dose wPlow 124 2.1  0.5
wP 123 2.1  0.3
2nd dose wPlow 121 4.2  0.5
wP 121 4.2  0.4
3rd dose wPlow 120 6.3  0.6
wP 119 6.3  0.4
Blood sampling wPlow 117 7.7  0.7
wP 119 7.7  0.6
a Number of individuals.
b Mean  standard deviation.
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theria and tetanus. As the lower limits of the CIs were not
lower than 	10% for the three studied parameters, the null
hypothesis of noninferiority of the wPlow vaccine was accepted.
Adverse events. Within the first 2 to 3 days after each injec-
tion, the parents and legal guardians of the vaccinees reported
local reactions, such as erythema (20 mm; 3.6% for the wPlow
vaccine group and 1.4% for the wP vaccine group) and pain
(5.3% for the wPlow vaccine group and 2.3% for the wP vaccine
group). Likewise, systemic reactions (body temperature,
39°C) were observed in both groups (3.8% for the wPlow
vaccine group and 2.0% for the wP vaccine group). Irritability
was reported after 4.4% of wPlow vaccine injections and 2.9%
of wP vaccine injections, respectively. Severe systemic adverse
effects after each diphtheria-tetanus-pertussis (DTP) vaccine
dose were not reported. None of the participants withdrew
from the study because of vaccine-related adverse events.
There were no significant differences between wPlow and wP
vaccine groups.
DISCUSSION
Studies of immune responses to pertussis vaccines suggest
that both B- and T-cell responses are elicited in humans (5, 7,
14) and mice (4, 33). By use of a murine model of infection, it
has been demonstrated that adoptive transfer of CD4 T cells
from immune mice confers protection against B. pertussis dur-
ing challenge in the absence of a detectable Ab response, but
also, passive Ab transfer protected mice from B. pertussis in-
fection (27). In an attempt to better understand the cell-me-
diated immune responses to pertussis vaccines in infants, we
evaluated the in vitro proliferation of T cells specific to B.
pertussis at one month after the third dose of vaccine was given.
We used a flow cytometry-based lymphocyte proliferation
assay that allowed the characterization of specific subpopula-
tion expansion in response to B. pertussis. We found that in-
fants vaccinated with the wP vaccine and those vaccinated with
the wPlow vaccine exhibited similar frequencies of B. pertussis-
specific proliferating CD4, CD8, and  cells, although
total CD3 cell proliferation in the wP vaccine group was
significantly higher.
We report here for the first time that, in humans, high
percentages of  cells are found in B. pertussis-stimulated
cultures (medians of 20.3% for wP and 16.8% for wPlow),
suggesting that these cells may play an important role in the
pertussis-specific response. T cells expressing the  receptor
were identified in the mid-1980s (11, 12, 15, 39) and are dis-
proportionately abundant within epithelial surfaces, including
those in the lung (26). Their intraepithelial distribution and
capacity for recognizing nonprotein antigens, sometimes in a
non-major histocompatibility complex-restricted fashion, have
led to their consideration as part of the first-line defense
against pathogens (23). In humans, large expansion of  T
cells after Mycobacterium bovis bacillus Calmette-Gue´rin vac-
cination and during infection with Mycobacterium tuberculosis,
Listeria monocytogenes, Brucella melitensis, and Ehrlichia
chaffeensis suggests their importance in the host response
(31, 42).
The activation of  T lymphocytes can lead to IFN-
production, which is instrumental in the upregulation of both
FIG. 3. IFN- (A), TNF-
 (B), and IL-10 (C) concentrations determined by ELISA (values are given in picograms per milliliter) by PBMC in
cultures without stimuli (control), with B. pertussis (Bp), or with PHA (F) stimulation in infants immunized with wPlow or wP vaccine. Bars indicate
medians, and the Mann-Whitney test was used to verify significances. n, number of individuals.
TABLE 2. Percentages of blast cells determined by flow cytometry in cultures of PBMC that were obtained from vaccinated infants and
incubated with medium alone, B. pertussis, or PHA
T-cell type
wPlow wP
na
Median % of specific T cells (95% CI)
na
Median % of specific T cells (95% CI)
Controlb B. pertussis PHA Controlb B. pertussis PHA
CD4 102 53.2 (49.6–58.3) 49.8 (45.9–52.7) 78.8 (74.7–80.5) 103 51.0 (47.4–55.8) 47.7 (45.0–51.6) 73.6 (69.6–76.2)
CD8 102 29.6 (25.6–33.1) 23.5 (22.3–26.5) 18.0 (15.4–20.7) 103 32.3 (28.7–34.8) 27.0 (25.4–29.7) 19.6 (17.1–24.8)
 28 5.7 (4.0–7.0) 16.8 (13.0–24.4) 1.9 (1.4–3.4) 27 5.9 (4.1–8.1) 20.3 (15.0–24.8) 1.9 (1.3–2.7)
a Number of individuals.
b Medium alone.
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macrophage and natural killer (NK) cell functions central to
early antibacterial protection prior to the 
 T-cell response
(23). IFN- also influences the downstream acquisition of a
Th1 phenotype by 
 T cells (42).  T cells thus bridge the
innate and acquired immune response by providing initial pro-
tection of epithelia from invasion and injury in instances where

 T cells are not yet operational and then downregulating
the antigen-specific adaptive immune response after the dan-
ger has passed to minimize potential immune-mediated injury
(40).
Although little is known about the importance of  T
lymphocytes during B. pertussis infection, a role for these cells
in the response of infected children has previously been sug-
gested via the migration of circulating  T cells to the air-
ways (9). Moreover, using a murine aerosol challenge model,
Zachariadis and coworkers demonstrated that the absence of
 T cells could influence the subsequent adaptive immune
response to B. pertussis antigens, as evidenced by a shift from
a Th1-type response to a Th2-type response against filamen-
tous hemagglutinin in TCR 	/	 mice (48).
Th1 cytokines are associated with protection in various B.
pertussis infection models, and in particular, in humans, pro-
tection against pertussis after infection or vaccination is deter-
mined by the presence of Th1 cytokines such as IL-12 and
IFN- (37). Also, the clearance of B. pertussis or protection
induced by wP vaccines is dependent on the production of Th1
cytokines, since IFN-- or IFN- receptor-defective mice and
mice depleted of NK cells, which infiltrate the lung and secrete
IFN- early in infection, develop disseminating lethal infec-
tions (13).
In this study, ELISA measurements of cytokine levels in
culture supernatants demonstrated significant increases in
IFN- and TNF-
 secretion by B. pertussis-stimulated PBMC.
Since there was no increase in IL-4 secretion, we speculate that
the cytokine production in response to B. pertussis was more
Th1-like for both vaccines. However, our assay did not permit
the identification of the cells which were secreting these cyto-
kines. Similar Th1 cytokine secretion profiles for adults (3) and
children (6, 30, 37) in response to cellular pertussis vaccines
have been reported. In contrast, T cells from children immu-
nized with aP vaccines can also secrete IL-5 following stimu-
lation with B. pertussis antigens and generate a type 2 effector
response (38).
Because of the bias against Th1-cell-polarizing cytokines, it
was initially thought that the neonatal immune system was
generally impaired or depressed. However, mounting evidence
suggests that, under some circumstances, human neonates
seem able to develop mature Th-cell responses, ranging from
deficient or deviant to fully mature, depending on the condi-
tions of antigen exposure (reviewed in reference 1). Our results
demonstrate that infants are able to mount Th1 responses to B.
pertussis after wP or wPlow vaccine administration.
The induction of protective Th1 responses by immunization
with the wP vaccine or by previous infection with B. pertussis
has been associated with IL-12 production by macrophages or
dendritic cells, and this has been linked with LPS present in the
wP preparations and in the live bacteria (29). LPS signaling
through TLR4 in innate immune cells plays a critical role in the
generation of inflammatory cytokines IL-12, IL-23, and IL-1,
which direct the induction of Th1 and Th17 cells in mice
immunized with wP vaccine. Furthermore, the cytokines se-
creted by these T-cell subtypes promote bacterial killing by
macrophages, a response that is further enhanced at the effec-
tor level by TLR4-mediated activation of macrophages. Thus,
TLR4 plays a critical role in the induction and in the effector
phase of the protective cellular immune response to B. pertussis
induced by vaccination (24), which could explain the lower
level of proliferation of CD3 T cells observed in wPlow vac-
cine group.
Additionally, the null hypothesis of noninferiority of wPlow
vaccine was accepted because the wPlow and wP vaccines elic-
ited similar anti-PT IgG GMTs and did not interfere in tetanus
or diphtheria seroconversion. Theoretically, the wPlow vaccine,
having 95% less LPS than the conventional vaccine, would
have weaker adjuvant activity and therefore produce a lower-
level Ab response. In this sense, we can understand the signif-
icantly higher level of total CD3 proliferation in the wP
vaccine group as a result of the LPS being linked to the host
TLR complex TLR4/MD-2 and the subsequent activation of
NF-B (35). Because there is no defined parameter for per-
tussis seroprotection (18), we could not estimate differences in
the proportions of protected infants.
Our surveillance system for severe adverse events following
immunization was able to detect an excellent primer safety
profile of wPlow and wP vaccines. DTP vaccines differ from
manufacturer to manufacturer because of the different Borde-
tella pertussis strains used for production. Some manufacturers
even use two different strains. There is a rare although serious
risk of a severe adverse event related to the pertussis compo-
nent of the DTP vaccine. The risks of encephalopathy and
convulsions vary according to the origin of the vaccine and the
strain used for production. These risks have been estimated as
1/19,496 for febrile convulsions, 1/76,133 for convulsion with-
out fever, and 3/1,000,000 for encephalopathy (17, 19). The wP
vaccine available in Brazil (licensed by the Butantan Institute)
has been administered free of charge to almost 100% of infants
TABLE 3. GMTs and 95% CI for serum anti-PT IgG levels of
infants vaccinated with three doses of wPlow or wP vaccine
Vaccine group na
Titer (IU/ml)
Geometric mean 95% CI
wPlow 114 12.65 10.46–15.30
wP 116 14.07 11.36–17.42
a Number of individuals.
TABLE 4. Protection against tetanus toxin and diphtheria toxin in
7-month-old infants vaccinated with three doses of the
wPlow or wP vaccine
Ab (0.10 IU/ml) and
vaccine
No. of subjects
considered
protected/total
% of subjects
protected
Mean 95% CI
Anti-tetanus toxin IgG
wPlow 107/112 95.5 89.9–98.5
wP 111/113 98.2 93.8–99.8
Anti-diphtheria toxin IgG
wPlow 104/113 92.0 85.4–96.3
wP 107/112 95.5 89.9–98.5
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in the past 15 years. More than 50 million doses have been
used, without major adverse effects. According to the Brazilian
Ministry of Health, pertussis incidence has declined from 10.8
per 100,000 in 1990 to 0.55 per 100,000 in 2005. In the same
period, diphtheria incidence decreased from 0.45 per 100,000
to 0.01 per 100,000 and tetanus incidence decreased from 1.0
per 100,000 to 0.25 per 100,000.
Since there were similar patterns of responses in the two
vaccinated groups, it is reasonable to assume that the low-LPS-
content cellular pertussis vaccine is capable of inducing a B.
pertussis-specific response and, consequently, is immunogenic.
Therefore, our data endorse further investigations with the
wPlow vaccine. On the other hand, it must be recognized that,
although the low-LPS-content cellular pertussis vaccine was
similar to the conventional whole-cell one, based on Th1-
polarized effector response and specific  T-cell expansion,
the overall data did suggest that the wP vaccine performed
modestly better with regard to specific CD3 T-cell prolifera-
tion.
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